Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9240468 | 0.75 | — | — | |
| SCHEMBL8887844 | 0.69 | — | — | |
| SCHEMBL4375192 | 0.67 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6007857 | 0.65 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1489101 | 0.63 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL6006272 | 0.63 | ALDH1A1 (0.30) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5507699 | 0.63 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1563629 | 0.63 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL17459430 | 0.63 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10495561 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | claimed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | claimed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | claimed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | claimed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | claimed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | claimed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | claimed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | claimed |
| US-20040106659-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | claimed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-1370534-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| EP-1370537-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | claimed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074751-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074748-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | claimed |
| US-9315514-B2 | 1,3-dioxanomorphides and 1,3-dioxanocodides | RHODES TECHNOLOGIES (US) | 2016-04-19 | — | — | US | disclosed |
| US-9273048-B2 | Spirocyclic morphinans and their use | PURDUE PHARMA L.P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150203495-A1 | SPIROCYCLIC MORPHINANS AND THEIR USE | PURDUE PHARMA L.P. | 2015-07-23 | — | — | US | disclosed |
| US-8957084-B2 | 7,8-cyclicmorphinan analogs | PURDUE PHARMA L.P. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8946255-B2 | Substituted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140187571-A1 | 7,8-Cyclicmorphinan Analogs | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140057932-A1 | 1,3-Dioxanomorphides and 1,3-Dioxanocodides | RHODES TECHNOLOGIES (US) | 2014-02-27 | — | — | US | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| EP-1676846-B1 | Hydantoin derivatives as MMP inhibitors | ASTRAZENECA AB (SE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | RUIPING LIU | 2009-07-09 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-7235579-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | RUIPING LIU | 2005-12-08 | — | — | US | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| EP-1435944-A1 | 4(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | Memory Pharmaceutical Corporation (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| US-20040106659-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370534-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370537-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003032981-A1 | 4-(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE DERIVATIVES AS PDE-4 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL SYNDROMES | MEMORY PHARMACEUTICALS CORPORATION (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074748-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074751-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885 |
| US-20030139406-A1 | Phosphodiesterase 4 inhibitors | PDE12, PDE4A, PDE5A | ALDH1A1 106/4885 |
| US-20150203495-A1 | SPIROCYCLIC MORPHINANS AND THEIR USE | OPRK1, OPRM1, OPRL1 | ALDH1A1 193/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885 |
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885 |
| US-20140187571-A1 | 7,8-Cyclicmorphinan Analogs | OPRL1, OPRM1, AVPR1A | ALDH1A1 1419/4885 |
| US-20140057932-A1 | 1,3-Dioxanomorphides and 1,3-Dioxanocodides | OPRD1, OPRL1, OPRK1 | ALDH1A1 453/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | ALDH1A1 612/4885 |
| US-20090176799-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE12, PDE3B | ALDH1A1 132/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | ALDH1A1 1381/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | ALDH1A1 573/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | ALDH1A1 1172/4885 |
| US-20050272803-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | ALDH1A1 132/4885 |
| US-20140187573-A1 | Substituted Morphinans and the Use Thereof | OPRL1, OPRM1, OPRK1 | ALDH1A1 763/4885 |
| US-20040106659-A1 | Metalloproteinase inhibitors | MMP9, TIMP3, MMP11 | ALDH1A1 712/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | ALDH1A1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.